{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T20:58:59Z","timestamp":1790888339409,"version":"4.1.0"},"reference-count":32,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2020,1,8]],"date-time":"2020-01-08T00:00:00Z","timestamp":1578441600000},"content-version":"vor","delay-in-days":7,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100007819","name":"Allergan","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007819","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["headachejournal.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Headache"],"published-print":{"date-parts":[[2020,1]]},"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To evaluate the long\u2010term safety and tolerability of ubrogepant for the acute treatment of migraine.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Ubrogepant is an oral, calcitonin gene\u2013related receptor antagonist in development for the acute treatment of migraine. The efficacy of ubrogepant was demonstrated in 2 phase 3 trials in which a significant improvement was observed in migraine headache pain, migraine\u2010associated symptoms, and ability to function.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This was a phase 3, multicenter, randomized, open\u2010label, 52\u2010week extension trial. Adults with migraine with or without aura entered the trial after completing one of 2 phase 3 lead\u2010in trials and were re\u2010randomized 1:1:1 to usual care, ubrogepant 50\u00a0mg, or ubrogepant 100\u00a0mg. Randomization to ubrogepant dose was blinded. Those randomized to usual care continued to treat migraine attacks with their own medication. The usual care arm was included in this trial to capture background rates of hepatic laboratory parameters and contextualize hepatic safety assessments. Safety and tolerability were the primary outcome measures. The safety population for the ubrogepant arms included all randomized participants who received at least 1 dose of treatment. All cases of alanine aminotransferase (ALT)\/aspartate aminotransferase (AST) elevations of \u22653 times the upper limit of normal were adjudicated by an independent panel of liver experts who were blinded to dose.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      The safety population included 1230 participants (404 in the ubrogepant 50\u2010mg group, 409 in the ubrogepant 100\u2010mg group, and 417 in the usual care group). Participants were on average 42\u00a0years of age, 90% (1106\/1230) female\u00a0and 85% (1043\/1230) white, with an average BMI of 30\u00a0kg\/m\n                      <jats:sup>2<\/jats:sup>\n                      . Throughout the trial, 21,454 migraine attacks were treated with 31,968 doses of ubrogepant. Treatment\u2010emergent adverse events (TEAEs) were reported by 268\/404 (66%) participants receiving ubrogepant 50\u00a0mg and 297\/409 (73%) receiving ubrogepant 100\u00a0mg. The most commonly reported TEAE was upper respiratory tract infection (&lt;12%); findings were similar across dose groups. Treatment\u2010related TEAEs were reported by 42\/404 (10%) participants in the ubrogepant 50\u2010mg group and 43\/409 (11%) in the ubrogepant 100\u2010mg group. Serious adverse events (SAEs) were reported by 9\/404 (2%) participants in the ubrogepant 50\u2010mg group and 12\/409 (3%) participants in the ubrogepant 100\u2010mg group. Twenty cases of ALT\/AST levels of \u22653 times the upper limit of normal were reported and reviewed by an independent clinical adjudication committee of liver experts. There were no cases of Hy\u2019s Law.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Long\u2010term intermittent use of ubrogepant 50 and 100\u00a0mg given as 1 or 2 doses per attack for the acute treatment of migraine was safe and well tolerated, as indicated by a low incidence of treatment\u2010related\u00a0TEAEs and SAEs and discontinuations due to adverse events in this 1\u2010year trial.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/head.13682","type":"journal-article","created":{"date-parts":[[2020,1,8]],"date-time":"2020-01-08T08:51:33Z","timestamp":1578473493000},"page":"141-152","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":87,"title":["Long\u2010Term Safety Evaluation of Ubrogepant for the Acute Treatment of Migraine: Phase 3, Randomized, 52\u2010Week Extension Trial"],"prefix":"10.1111","volume":"60","author":[{"given":"Jessica","family":"Ailani","sequence":"first","affiliation":[{"name":"Medstar Georgetown University Hospital Washington DC USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard B.","family":"Lipton","sequence":"additional","affiliation":[{"name":"Albert Einstein College of Medicine and Montefiore Headache Center Bronx NY USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan","family":"Hutchinson","sequence":"additional","affiliation":[{"name":"Orange County Migraine &amp; Headache Center Irvine CA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kerry","family":"Knievel","sequence":"additional","affiliation":[{"name":"Barrow Neurological Institute Phoenix AZ USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaifeng","family":"Lu","sequence":"additional","affiliation":[{"name":"Allergan plc Madison NJ USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Butler","sequence":"additional","affiliation":[{"name":"Allergan plc Madison NJ USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sung Yun","family":"Yu","sequence":"additional","affiliation":[{"name":"Allergan plc Madison NJ USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle","family":"Finnegan","sequence":"additional","affiliation":[{"name":"Allergan plc Madison NJ USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lawrence","family":"Severt","sequence":"additional","affiliation":[{"name":"Allergan plc Madison NJ USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joel M.","family":"Trugman","sequence":"additional","affiliation":[{"name":"Allergan plc Madison NJ USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2020,1,8]]},"reference":[{"key":"e_1_2_9_2_1","doi-asserted-by":"publisher","DOI":"10.1177\/0333102417738202"},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(17)30299-5"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)32154-2"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.1111\/head.13301"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.1111\/head.13254"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.mayocp.2016.02.013"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.1185\/030079904125004178"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.1111\/head.13433"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.1186\/1129-2377-15-3"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.1111\/head.12550"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(10)70005-3"},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.1517\/14740338.2015.1026325"},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1526-4610.2007.00752.x"},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.1111\/head.13407"},{"issue":"2","key":"e_1_2_9_16_1","first-page":"63","article-title":"Assessing unmet treatment needs and associated disability in persons with migraine: Results from migraine in America symptoms and treatment (MAST) study [abstract OR02]","volume":"58","author":"Lipton RB","year":"2018","journal-title":"Headache"},{"key":"e_1_2_9_17_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1526-4610.2003.03034.x"},{"key":"e_1_2_9_18_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41582-018-0003-1"},{"key":"e_1_2_9_19_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrneurol.2010.127"},{"key":"e_1_2_9_20_1","doi-asserted-by":"publisher","DOI":"10.1177\/0333102416653233"},{"key":"e_1_2_9_21_1","first-page":"1287","article-title":"Ubrogepant for the acute treatment of migraine: Efficacy, safety, tolerability, and functional impact outcomes from a single attack phase III study, ACHIEVE 1 [abstract IOR\u201001LB]","volume":"58","author":"Dodick DW","year":"2018","journal-title":"Headache"},{"key":"e_1_2_9_22_1","first-page":"1315","article-title":"Efficacy, safety, and tolerability of ubrogepant for the acute treatment of migraine: Results from a single attack phase III study, ACHIEVE II [abstract PS111LB]","volume":"58","author":"Lipton RB","year":"2018","journal-title":"Headache"},{"key":"e_1_2_9_23_1","doi-asserted-by":"publisher","DOI":"10.1002\/pds.1211"},{"key":"e_1_2_9_24_1","volume-title":"Guidance for Industry Drug\u2010Induced Liver Injury: Premarketing Clinical Evaluation","year":"2009"},{"key":"e_1_2_9_25_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13311-018-0617-4"},{"key":"e_1_2_9_26_1","doi-asserted-by":"publisher","DOI":"10.1177\/0333102415584308"},{"key":"e_1_2_9_27_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000000771"},{"key":"e_1_2_9_28_1","doi-asserted-by":"publisher","DOI":"10.1177\/0333102411398399"},{"key":"e_1_2_9_29_1","first-page":"80","article-title":"Safety and tolerability of ubrogepant following intermittent, high\u2010frequency dosing [abstract P88]","volume":"59","author":"Goadsby PJ","year":"2019","journal-title":"Headache"},{"issue":"1","key":"e_1_2_9_30_1","first-page":"110","article-title":"Efficacy is maintained with long\u2010term intermittent use of ubrogepant for the acute treatment of migraine [abstract P135]","volume":"59","author":"Lipton RB","year":"2019","journal-title":"Headache"},{"key":"e_1_2_9_31_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1468-2982.1999.019007676.x"},{"key":"e_1_2_9_32_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1526-4610.2001.111006057.x"},{"key":"e_1_2_9_33_1","first-page":"A180","article-title":"Epidemiology of chronic daily headache in adolescents [abstract]","volume":"68","author":"Grosberg B","year":"2007","journal-title":"Neurology"}],"updated-by":[{"DOI":"10.1111\/head.14080","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2021,3,18]],"date-time":"2021-03-18T00:00:00Z","timestamp":1616025600000}}],"container-title":["Headache: The Journal of Head and Face Pain"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fhead.13682","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/head.13682","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/head.13682","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/headachejournal.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/head.13682","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,2]],"date-time":"2025-11-02T09:25:49Z","timestamp":1762075549000},"score":1,"resource":{"primary":{"URL":"https:\/\/headachejournal.onlinelibrary.wiley.com\/doi\/10.1111\/head.13682"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1]]},"references-count":32,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,1]]}},"alternative-id":["10.1111\/head.13682"],"URL":"https:\/\/doi.org\/10.1111\/head.13682","archive":["Portico"],"relation":{},"ISSN":["0017-8748","1526-4610"],"issn-type":[{"value":"0017-8748","type":"print"},{"value":"1526-4610","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,1]]},"assertion":[{"value":"2019-09-27","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-01-08","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}